Trial Profile
A Phase I Study of MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs MK 2206 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 18 Apr 2012 Actual patient number (24) added as reported by ClinicalTrials.gov.
- 09 Feb 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 06 Jan 2012 Planned end date changed from 1 Apr 2012 to 1 Sep 2011 as reported by ClinicalTrials.gov.